KCT0001539进行中（未招募）未知
Phase I Study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of HM95573 in solid tumors
Hanmi Pharm0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Patients must be 19 years of age or older
- •2. Subjects who have provided voluntary consent to participate in the study, and signed the written consent document.
- •3. Estimated life expectancy of at least 12 weeks
- •4. Histologically or cytologically confirmed advanced solid tumor
排除标准
- •1.Symptomatic or uncontrolled central nervous system metastases
- •2. Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug.
- •3. Patients who, in the investigator’s opinion, are not suitable for the study for any other reason.
研究者
相似试验
招募中
1 期
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in men with biochemical recurrence of prostate cancerbiochemical recurrence after curativelyintended therapy for localized PCDRKS00031816niversitätsklinikum Tübingen38
已完成
不适用
Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics and pharmacodynamics of monoclonal antibody TB31F in healthy malaria-naïve adults in the NetherlandsmalariaNL-OMON50099Radboud Universitair Medisch Centrum25
已完成
1 期
Safety, tolerability and pharmacokinetics study of WCK 2349 (in single doses) in healthy male volunteer.CTRI/2009/091/000377Wockhardt Ltd84
已完成
不适用
A Phase I study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of HTX-011-19 (a long acting formulation of 5% bupivacaine and 0.15% meloxicam) and HTX-011-49 (a long acting formulation of 2.5% bupivacaine and 0.075% meloxicam) after subcutaneous administration in healthy subjects.post-operative painanalgesicsNL-OMON41936Heron Therapeutics, Inc.46
已完成
1 期
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisBronchiectasisACTRN12614001199606TB4 Sweden AB30